Table 3 Patient demographics and clinical characteristics
|  | Global (n = 1195) | UK (n = 127) | France (n = 254) | Germany (n = 179) | Italy (n = 155) | Spain (n = 173) | EU5 (n = 888) | Japan (n = 125) | US (n = 182) |
|---|---|---|---|---|---|---|---|---|---|
Age, mean, years (SD) | 72.1 (8.01) | 70.7 (7.75) | 73.7 (7.97) | 70.3 (6.82) | 73.7 (8.10) | 71.3 (8.08) | 72.1 (7.89) | 75.3 (7.46) | 69.4 (8.10) |
Employment status at time of data collection, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Working | 158 (13.2) | 24 (18.9) | 5 (2.0) | 11 (6.1) | 17 (11.0) | 12 (6.9) | 69 (7.8) | 27 (21.6) | 62 (34.1) |
 Not working | 1015 (84.9) | 102 (80.3) | 247 (97.2) | 168 (93.9) | 132 (85.2) | 157 (90.8) | 806 (90.8) | 90 (72) | 119 (65.4) |
 Don’t know | 22 (1.8) | 1 (0.8) | 2 (0.8) | 0 (0.0) | 6 (3.9) | 4 (2.3) | 13 (1.5) | 8 (6.4) | 1 (0.5) |
ECOG performance status at time of data collection, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 0–1 | 941 (78.7) | 111 (87.4) | 186 (73.2) | 118 (65.9) | 125 (80.6) | 152 (87.9) | 692 (77.9) | 114 (91.2) | 135 (74.2) |
 2–4 | 248 (20.8) | 16 (12.6) | 64 (25.2) | 61 (34.1) | 28 (18.1) | 21 (12.1) | 190 (21.4) | 11 (8.8) | 47 (25.8) |
 Unknown/not assessed | 6 (0.5) | 0 (0.0) | 4 (1.6) | 0 (0.0) | 2 (1.3) | 0 (0.0) | 6 (0.7) | 0 (0.0) | 0 (0.0) |
Disease status at time of data collection, n (%) | 1189 | 126 | 252 | 178 | 153 | 173 | 882 | 125 | 182 |
 Disease progressing | 55 (4.6) | 1 (0.8) | 2 (0.8) | 29 (16.3) | 3 (2.0) | 7 (4.0) | 42 (4.8) | 3 (2.4) | 10 (5.5) |
 Stable | 444 (37.3) | 19 (15.1) | 76 (30.2) | 76 (42.7) | 66 (43.1) | 53 (30.6) | 290 (32.9) | 75 (60) | 79 (43.4) |
 Responding to treatment | 690 (58.0) | 106 (84.1) | 174 (69.0) | 73 (41.0) | 84 (54.9) | 113 (65.3) | 550 (62.4) | 47 (37.6) | 93 (51.1) |
Patient’s family history of prostate cancer, n (%) | 1195 | 127 | 254 | 179 | 155 | 173 | 888 | 125 | 182 |
 Has a family history | 111 (9.3) | 9 (7.1) | 18 (7.1) | 30 (16.8) | 8 (5.2) | 17 (9.8) | 82 (9.2) | 5 (4.0) | 24 (13.2) |
 Does not have a family history | 997 (83.4) | 106 (83.5) | 224 (88.2) | 142 (79.3) | 130 (83.9) | 150 (86.7) | 752 (84.7) | 99 (79.2) | 146 (80.2) |
 Don’t know | 87 (7.3) | 12 (9.4) | 12 (4.7) | 7 (3.9) | 17 (11.0) | 6 (3.5) | 54 (6.1) | 21 (16.8) | 12 (6.6) |
Sites of metastases at time of data collection, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Bone | 1020 (85.4) | 118 (92.9) | 239 (94.1) | 136 (76) | 135 (87.1) | 160 (92.5) | 788 (88.7) | 109 (87.2) | 123 (67.6) |
 Brain | 8 (0.7) | 1 (0.8) | 1 (0.4) | 3 (1.7) | 0 (0.0) | 0 (0.0) | 5 (0.6) | 1 (0.8) | 2 (1.1) |
 Lung | 97 (8.1) | 12 (9.4) | 25 (9.8) | 11 (6.1) | 10 (6.5) | 17 (9.8) | 75 (8.4) | 5 (4.0) | 17 (9.3) |
 Pancreas | 4 (0.3) | 0 (0.0) | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.1) | 0 (0.0) | 3 (1.6) |
 Liver | 73 (6.1) | 7 (5.5) | 25 (9.8) | 11 (6.1) | 6 (3.9) | 11 (6.4) | 60 (6.8) | 1 (0.8) | 12 (6.6) |
 Adrenal glands | 17 (1.4) | 0 (0.0) | 5 (2.0) | 4 (2.2) | 2 (1.3) | 3 (1.7) | 14 (1.6) | 1 (0.8) | 2 (1.1) |
 Peritoneal | 30 (2.5) | 0 (0.0) | 5 (2.0) | 10 (5.6) | 2 (1.3) | 0 (0.0) | 17 (1.9) | 0 (0.0) | 13 (7.1) |
Non-regional/distant lymph nodes | 368 (30.8) | 38 (29.9) | 86 (33.9) | 57 (31.8) | 55 (35.5) | 63 (36.4) | 299 (33.7) | 23 (18.4) | 46 (25.3) |
 Other | 6 (0.5) | 0 (0.0) | 1 (0.4) | 1 (0.6) | 0 (0.0) | 1 (0.6) | 3 (0.3) | 0 (0.0) | 3 (1.6) |
Number of bone metastases sites identified, n (%) | 850 | 76 | 209 | 117 | 111 | 139 | 652 | 94 | 104 |
 1–3 lesions | 435 (51.2) | 36 (47.4) | 104 (49.8) | 60 (51.3) | 54 (48.6) | 60 (43.2) | 314 (48.2) | 57 (60.6) | 64 (61.5) |
 4 + lesions | 415 (48.8) | 40 (52.6) | 105 (50.2) | 57 (48.7) | 57 (51.4) | 79 (56.8) | 338 (51.8) | 37 (39.4) | 40 (38.5) |
Risk status, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Low-risk | 674 (56.4) | 58 (45.7) | 133 (52.4) | 115 (64.2) | 94 (60.6) | 89 (51.4) | 489 (55.1) | 55 (44.0) | 130 (71.4) |
 High-risk | 433 (36.2) | 49 (38.6) | 103 (40.6) | 54 (30.2) | 44 (28.4) | 78 (45.1) | 328 (36.9) | 60 (48.0) | 45 (24.7) |
 Don’t know | 88 (7.4) | 20 (15.7) | 18 (7.1) | 10 (5.6) | 17 (11.0) | 6 (3.5) | 71 (8.0) | 10 (8.0) | 7 (3.8) |
Disease volume, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Low volume | 598 (50.0) | 50 (39.4) | 117 (46.1) | 102 (57.0) | 67 (43.2) | 76 (43.9) | 412 (46.4) | 77 (61.6) | 109 (59.9) |
 High volume | 409 (34.2) | 34 (26.8) | 104 (40.9) | 54 (30.2) | 58 (37.4) | 75 (43.4) | 325 (36.6) | 33 (26.4) | 51 (28.0) |
 Don’t know | 188 (15.7) | 43 (33.9) | 33 (13.0) | 23 (12.8) | 30 (19.4) | 22 (12.7) | 151 (17.0) | 15 (12.0) | 22 (12.1) |
Most recent PSA result at time of data collection (ng/mL), n | 1037 | 101 | 215 | 158 | 139 | 161 | 774 | 116 | 147 |
 Mean (SD) | 20.1 (60.42) | 30.8 (81.17) | 26.5 (70.03) | 20.8 (67.75) | 11.3 (17.84) | 18.4 (38.90) | 21.5 (59.59) | 7.4 (20.95) | 22.7 (81.32) |
Most recent haemoglobin test result at time of data collection (g/dL), n | 615 | 66 | 116 | 74 | 87 | 133 | 476 | 79 | 60 |
 Mean (SD) | 12.0 (1.48) | 11.7 (1.44) | 12.3 (1.29) | 11.8 (1.71) | 11.8 (1.29) | 12.0 (1.44) | 12.0 (1.44) | 12.3 (1.36) | 12.3 (1.87) |
Most recent alkaline phosphatase result at time of data collection (U/L), n | 539 | 65 | 99 | 42 | 71 | 115 | 392 | 93 | 54 |
 Mean (SD) | 196.8 (141.55) | 179.2 (118.50) | 181.5 (132.55) | 162.0 (94.58) |  209.2 (187.94) |  189.2 (134.52) |  186.3 (139.34) | 256.8 (146.57) |  169.3 (115.83) |